1932

Abstract

The widespread abuse of prescription opioids and a dramatic increase in the availability of illicit opioids have created what is commonly referred to as the opioid epidemic. The magnitude of this epidemic is startling: About 4% of the adult US population misuses prescription opioids, and in 2015, more than 33,000 deaths were attributable to overdose with licit and illicit opioids. Increasing the availability of medication-assisted treatments (such as buprenorphine and naltrexone), the use of abuse-deterrent formulations, and the adoption of US Centers for Disease Control and Prevention prescribing guidelines all constitute short-term approaches to quell this epidemic. However, with more than 125 million Americans suffering from either acute or chronic pain, the development of effective alternatives to opioids, enabled at least in part by a fuller understanding of the neurobiological bases of pain, offers the best long-term solution for controlling and ultimately eradicating this epidemic.

Loading

Article metrics loading...

/content/journals/10.1146/annurev-pharmtox-010617-052534
2018-01-06
2024-04-22
Loading full text...

Full text loading...

/deliver/fulltext/pharmtox/58/1/annurev-pharmtox-010617-052534.html?itemId=/content/journals/10.1146/annurev-pharmtox-010617-052534&mimeType=html&fmt=ahah

Literature Cited

  1. Volkow ND, McLellan AT. 1.  2016. Opioid abuse in chronic pain—misconceptions and mitigation strategies. N. Engl. J. Med. 374:1253–63 [Google Scholar]
  2. Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H. 2.  et al. 2016. Nonmedical prescription opioid use and DSM-5 nonmedical prescription opioid use disorder in the United States. J. Clin. Psychiatry 77:772–80 [Google Scholar]
  3. Rudd R, Seth P, David F, Scholl L. 3.  2016. Increases in drug and opioid-involved overdose deaths—United States, 2010–2015. MMWR Morb. Mortal. Wkly. Rep. 65:1445–52 [Google Scholar]
  4. Peterson AB, Gladden RM, Delcher C, Spies E, Garcia-Williams A. 4.  et al. 2016. Increases in fentanyl-related overdose deaths - Florida and Ohio, 2013–2015. MMWR Morb. Mortal. Wkly. Rep. 65:844–49 [Google Scholar]
  5. Morrone WR. 5.  2016. President's message: Food and Drug Administration approved naloxone and continued use of improvised nasal naloxone: What is a treatment advocate and educator to do?. J. Addict. Dis. 35:339–45 [Google Scholar]
  6. Compton WM, Jones CM, Baldwin GT. 6.  2016. Relationship between nonmedical prescription-opioid use and heroin use. N. Engl. J. Med. 374:154–63 [Google Scholar]
  7. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. 7.  2014. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry 71:821–26 [Google Scholar]
  8. Skolnick P, Volkow ND. 8.  2016. Re-energizing the development of pain therapeutics in light of the opioid epidemic. Neuron 92:294–97 [Google Scholar]
  9. Tolia VN, Patrick SW, Bennett MM, Murthy K, Sousa J. 9.  et al. 2015. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N. Engl. J. Med. 372:2118–26 [Google Scholar]
  10. Valdiserri R, Khalsa J, Dan C, Holmberg S, Zibbell J. 10.  et al. 2014. Confronting the emerging epidemic of HCV infection among young injection drug users. Am. J. Public Health 104:816–21 [Google Scholar]
  11. Peters PJ, Pontones P, Hoover KW, Patel MR, Galang RR. 11.  et al. 2016. HIV infection linked to injection use of oxymorphone in Indiana, 2014–2015. N. Engl. J. Med. 375:229–39 [Google Scholar]
  12. Compton WM, Volkow ND. 12.  2006. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol. Depend. 81:103–7 [Google Scholar]
  13. Anson P. 13.  2016. AMA drops pain as vital sign. Pain News Netw June 16. https://www.painnewsnetwork.org/stories/2016/6/16/ama-drops-pain-as-vital-sign
  14. Van Zee A. 14.  2009. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am. J. Public Health 99:221–27 [Google Scholar]
  15. Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T. 15.  et al. 1999. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. Clin. J. Pain 15:179–83 [Google Scholar]
  16. Stambaugh JE, Reder RF, Stambaugh MD, Stambaugh H, Davis M. 16.  2001. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients. J. Clin. Pharmacol. 41:500–6 [Google Scholar]
  17. Cicero TJ, Inciardi JA, Muñoz A. 17.  2005. Trends in abuse of OxyContin® and other opioid analgesics in the United States: 2002–2004. J. Pain 6:662–72 [Google Scholar]
  18. 18. US Dep. Health. Hum. Serv., Food Drug Adm., Cent. Drug Eval. Res. 2015. Abuse-Deterrent Opioids—Evaluation and Labeling: Guidance for Industry Silver Spring, MD: Food Drug Adm http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm334743.pdf
  19. Dart RC, Surratt HL, Cicero TJ, Parrino MW, Severtson SG. 19.  et al. 2015. Trends in opioid analgesic abuse and mortality in the United States. N. Engl. J. Med. 372:241–48 [Google Scholar]
  20. Webster LR, Odinecs A, Herzog S, Eldon M, Medve R. 20.  2012. Multiple dose pharmacokinetics and pharmacodynamics of the new oral opioid analgesic NKTR-181 Presented at Am. Acad. Pain Med., 28th Annu. Meet Palm Springs, CA, Pain Med. Poster 282B
  21. 21. Nektar. 2017. NKTR-181 San Francisco: Nektar http://www.nektar.com/pipeline/rd-pipeline/nktr-181
  22. Jenkins T. 22.  2016. Bio-activated opioid drugs with unprecedented oral and non-oral abuse-resistance Presented at Am. Psychiat. Assoc. 169th Annu. Meet., Atlanta, May 15, Symposium 4307. https://www.sbir.gov/sbirsearch/detail/1046491
  23. 23. Natl. Inst. Drug Abus. 2012. Principles of Drug Addiction Treatment: A Research-Based Guide Bethesda, MD: Natl. Inst. Health. , 3rd ed.. https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition/preface
  24. Acri J, Skolnick P. 24.  2013. Pharmacotherapy of substance use disorders. Neurobiology of Mental Illness DS Charney, JD Buxbaum, P Sklar, EJ Nestler 761–71 New York: Oxford Univ. Press, 4th ed.. [Google Scholar]
  25. 25. Indivior. 2015. Annual Report 2015 Richmond, VA: http://www.indivior.com/wp-content/uploads/2016/04/Indivior-Annual-Report-2015.pdf
  26. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT. 26.  et al. 2014. Primary care-based buprenorphine taper versus maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern. Med. 174:1947–54 [Google Scholar]
  27. 27. US Food Drug Adm. 2016. FDA approves first buprenorphine implant for treatment of opioid dependence News Release, May 26. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503719.htm
  28. Rosenthal RN, Lofwall MR, Kim S. 28.  2016. Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: a randomized clinical trial. JAMA 316:282–90 [Google Scholar]
  29. 29. Braeburn Pharm. 2017. Pipeline https://braeburnpharmaceuticals.com/pipeline/
  30. 30. Indivior. 2017. A Pipeline Innovated by the Global Human Crisis http://www.indivior.com/research-and-development/
  31. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR. 31.  et al. 2011. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377:1506–13 [Google Scholar]
  32. Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY. 32.  et al. 2016. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N. Engl. J. Med. 374:1232–42 [Google Scholar]
  33. Baser O, Chalk M, Fiellin DA, Gastfriend DR. 33.  2011. Cost and utilization outcomes of opioid-dependence treatments. Am. J. Manag. Care 17:Suppl. 8S235–48 [Google Scholar]
  34. Krupitsky E, Zvartau E, Blokhina E, Verbitskaya E, Wahlgren V. 34.  et al. 2012. Randomized trial of long-acting sustained-release naltrexone implant versus oral naltrexone or placebo for preventing relapse to opioid dependence. Arch. Gen. Psychiatry 69:973–81 [Google Scholar]
  35. Behar E, Santos GM, Wheeler E, Rowe C, Coffin PO. 35.  2015. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend. 148:209–12 [Google Scholar]
  36. Gwira Baumblatt JA, Wiedeman C, Dunn JR, Schaffner W, Paulozzi LJ. 36.  et al. 2014. High-risk use by patients prescribed opioids for pain and its role in overdose deaths. JAMA Intern. Med. 174:796–801 [Google Scholar]
  37. Park TW, Lin LA, Hosanagar A, Kogowski A, Paige K. 37.  et al. 2016. Understanding risk factors for opioid overdose in clinical populations to inform treatment and policy. J. Addict. Med. 10:369–81 [Google Scholar]
  38. Doe-Simkins M, Quinn E, Xuan Z, Sorensen-Alawad A, Hackman H. 38.  et al. 2014. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health 14:297 [Google Scholar]
  39. Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. 39.  2008. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther. Drug Monit. 30:490–96 [Google Scholar]
  40. Grassin-Delyle S, Buenestado A, Naline E, Faisy C, Blouquit-Laye S. 40.  et al. 2012. Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. Pharmacol. Ther. 134:366–79 [Google Scholar]
  41. 41. Teleflex Med. 2016. Urgent medical device recall notification: LMA® MAD Nasalintranasal mucosal atomization device News Release, Oct. 27. http://www.ct.gov/dmhas/lib/dmhas/newsworthy/mad_recall.pdf [Google Scholar]
  42. Doe-Simkins M, Walley AY, Epstein A, Moyer P. 42.  2009. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am. J. Public Health 99:788–91 [Google Scholar]
  43. Kelly AM, Kerr D, Dietze P, Patrick I, Walker T. 43.  et al. 2005. Randomised trial of intranasal versus intramuscular naloxone in prehospital treatment for suspected opioid overdose. Med. J. Aust. 182:24–27 [Google Scholar]
  44. Kerr D, Kelly AM, Dietze P, Jolley D, Barger B. 44.  2009. Randomized controlled trial comparing the effectiveness and safety of intranasal and intramuscular naloxone for the treatment of suspected heroin overdose. Addiction 104:2067–74 [Google Scholar]
  45. Edwards ET, Edwards ES, Davis E, Mulcare M, Wiklund M. 45.  et al. 2015. Comparative usability study of a novel auto-injector and an intranasal system for naloxone delivery. Pain Ther 4:89–105 [Google Scholar]
  46. 46. US Food Drug Adm. 2014. EVZIO (Naloxone Hydrochloride Injection) Auto-Injector for Intramuscular or Subcutaneous Use Silver Spring, MD: Food Drug Adm http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205787Orig1s000lbl.pdf
  47. 47. US Food Drug Adm. 2015. NARCAN® (Naloxone Hydrochloride) Nasal Spray Silver Spring, MD: Food Drug Adm http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/208411lbl.pdf
  48. Krieter P, Chiang N, Gyaw S, Skolnick P, Crystal R. 48.  et al. 2016. Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose. J. Clin. Pharmacol. 56:1243–53 [Google Scholar]
  49. 49. EMS World. 2017. FDA approves Adapt Pharma's NARCAN Nasal Spray 2mg News Release, Jan. 25. http://www.emsworld.com/pressrelease/12298772/fda-approves-adapt-pharma-s-narcan-nasal-spray-2mg
  50. Zuckerman M, Weisberg SN, Boyer EW. 50.  2014. Pitfalls of intranasal naloxone. Prehosp. Emerg. Care 18:550–54 [Google Scholar]
  51. Strang J, McDonald R, Tas B, Day E. 51.  2016. Clinical provision of improvised nasal naloxone without experimental testing and without regulatory approval: imaginative shortcut or dangerous bypass of essential safety procedures?. Addiction 111:574–82 [Google Scholar]
  52. Compton WM, Volkow ND, Throckmorton DC, Lurie P. 52.  2013. Expanded access to opioid overdose intervention: research, practice, and policy needs. Ann. Intern. Med. 158:65–66 [Google Scholar]
  53. Dowell D, Haegerich TM, Chou R. 53.  2016. CDC guideline for prescribing opioids for chronic pain–United States, 2016.. JAMA 315:1624–45 [Google Scholar]
  54. Skolnick P. 54.  2015. Biologic approaches to treat substance-use disorders. Trends Pharmacol. Sci. 36:628–35 [Google Scholar]
  55. Anderson AL, Li SH, Biswas K, McSherry F, Holmes T. 55.  et al. 2012. Modafinil for the treatment of methamphetamine dependence. Drug Alcohol Depend. 120:135–41 [Google Scholar]
  56. Somoza EC, Winship D, Gorodetzky CW, Lewis D, Ciraulo DA. 56.  et al. 2013. A multisite, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of vigabatrin for treating cocaine dependence. JAMA Psychiatry 70:630–37 [Google Scholar]
  57. Bonese KF, Wainer BH, Fitch FW, Rothberg RM, Schuster CR. 57.  1974. Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252:708–10 [Google Scholar]
  58. Bremer PT, Schlosburg JE, Lively JM, Janda KD. 58.  2014. Injection route and TLR9 agonist addition significantly impact heroin vaccine efficacy. Mol. Pharmaceut. 11:1075–80 [Google Scholar]
  59. Matyas GR, Rice KC, Cheng K, Li F, Antoline JF. 59.  et al. 2014. Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine. Vaccine 32:1473–79 [Google Scholar]
  60. Bremer PT, Kimishima A, Schlosburg JE, Zhou B, Collins KC. 60.  et al. 2016. Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew. Chem. Int. Ed. Engl. 55:3772–75 [Google Scholar]
  61. Kimishima A, Wenthur C, Zhou B, Janda KD. 61.  2016. An advance in prescription opioid vaccines: overdose mortality reduction and extraordinary alteration of drug half-life. ACS Chem. Biol. 12:36–40 [Google Scholar]
  62. Martell BA, Orson FM, Poling J, Mitchell E, Rossen RD. 62.  et al. 2009. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 66:1116–23 [Google Scholar]
  63. Hatsukami DK, Jorenby DE, Gonzales D, Rigotti NA, Glover ED. 63.  et al. 2011. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 89:392–99 [Google Scholar]
  64. Heidbreder CA, Newman AH. 64.  2010. Current perspectives on selective dopamine D3 receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann. N. Y. Acad. Sci. 1187:4–34 [Google Scholar]
  65. Bubar MJ, Cunningham KA. 65.  2008. Prospects for serotonin 5-HT2R pharmacotherapy in psychostimulant abuse. Prog. Brain Res. 172:319–46 [Google Scholar]
  66. Higgins GA, Fletcher PJ. 66.  2015. Therapeutic potential of 5-HT2C receptor agonists for addictive disorders. ACS Chem. Neurosci. 6:1071–88 [Google Scholar]
  67. Mugnaini M, Iavarone L, Cavallini P, Griffante C, Oliosi B. 67.  et al. 2013. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Neuropsychopharmacology 38:302–12 [Google Scholar]
  68. Boateng CA, Bakare OM, Zhan J, Banala AK, Burzynski C. 68.  et al. 2015. High affinity dopamine D3 receptor (D3R)-selective antagonists attenuate heroin self-administration in wild-type but not D3R knockout mice. J. Med. Chem. 58:6195–213 [Google Scholar]
  69. Shanahan WR, Rose JE, Glicklich A, Stubbe S, Sanchez-Kam M. 69.  2016. Lorcaserin for smoking cessation and associated weight gain: a randomized 12-week clinical trial. Nicotine Tob. Res. 19:944–51 [Google Scholar]
  70. Neelakantan H, Holliday E, Fox R, Stutz S, Comer S. 70.  et al. 2017. Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. ACS Chem. Neurosci. 8:1065–73 [Google Scholar]
  71. Skolnick P, Volkow ND. 71.  2012. Addiction therapeutics: obstacles and opportunities. Biol. Psychiatry 72:890–91 [Google Scholar]
  72. Nahin RL. 72.  2015. Estimates of pain prevalence and severity in adults: United States, 2012.. J. Pain 16:769–80 [Google Scholar]
  73. Miller G. 73.  2010. Is pharma running out of brainy ideas?. Science 329:502–4 [Google Scholar]
  74. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S. 74.  et al. 1996. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid-receptor gene. Nature 383:819–23 [Google Scholar]
  75. Kieffer BL. 75.  1999. Opioids: first lessons from knockout mice. Trends Pharmacol. Sci. 20:19–26 [Google Scholar]
  76. Kenakin T. 76.  2011. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336:296–302 [Google Scholar]
  77. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG. 77.  et al. 1999. Enhanced morphine analgesia in mice lacking β-arrestin 2. Science 286:2495–98 [Google Scholar]
  78. Raehal KM, Walker JKL, Bohn LM. 78.  2005. Morphine side effects in β-arrestin 2 knockout mice. J. Pharmacol. Exp. Ther. 314:1195–201 [Google Scholar]
  79. Dewire SM, Yamashita DS, Rominger DH, Liu G, Cowan CL. 79.  et al. 2013. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J. Pharmacol. Exp. Ther. 344:708–17 [Google Scholar]
  80. Manglik A, Lin H, Aryal DK, McCorvy JD, Dengler D. 80.  et al. 2016. Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185–90 [Google Scholar]
  81. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG. 81.  2000. μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence. Nature 408:720–23 [Google Scholar]
  82. Bohn LM, Gainetdinov RR, Sotnikova TD, Medvedev IO, Lefkowitz RJ. 82.  et al. 2003. Enhanced rewarding properties of morphine, but not cocaine, in β arrestin-2 knock-out mice. J. Neurosci. 23:10265–73 [Google Scholar]
  83. Viscusi ER, Webster L, Kuss M, Daniels S, Bolognese JA. 83.  et al. 2016. A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain. Pain 157:264–72 [Google Scholar]
  84. Soergel DG, Subach RA, Burnham N, Lark MW, James IE. 84.  et al. 2014. Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers. Pain 155:1829–35 [Google Scholar]
  85. Majumdar S, Grinnell S, Le RV Burgman M, Polikar L. 85.  et al. 2011. Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. PNAS 108:19778–83 [Google Scholar]
  86. Wieskopf JS, Pan YX, Marcovitz J, Tuttle AH, Majumdar S. 86.  et al. 2014. Broad-spectrum analgesic efficacy of IBNtxA is mediated by exon 11-associated splice variants of the mu-opioid receptor gene. Pain 155:2063–70 [Google Scholar]
  87. Scannell JW, Blanckley A, Boldon H, Warrington B. 87.  2012. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11:191–200 [Google Scholar]
  88. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB. 88.  et al. 2014. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin. J. Pain 30:557–64 [Google Scholar]
  89. 89. Interag. Pain Res. Coord. Comm. 2016. National Pain Strategy outlines actions for improving pain care in America News Release, Mar. 18. https://iprcc.nih.gov/National_Pain_Strategy/NPS_Main.htm
  90. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R. 90.  et al. 2015. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 14:162–73 [Google Scholar]
  91. Arnold LM, Russel IJ, Diri EW, Duan WR, Young JP. 91.  et al. 2008. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J. Pain 9:792–805 [Google Scholar]
  92. Derry S, Gill D, Phillips T, Moore RA. 92.  2012. Milnacipran for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst. Rev. 2012:CD008244 [Google Scholar]
  93. Cao L, McDonnell A, Nitzsche A, Alexandrou A, Saintot PP. 93.  et al. 2016. Pharmacological reversal of a pain phenotype in iPSC-derived sensory neurons and patients with inherited erythromelalgia. Sci. Transl. Med. 8:335ra56 [Google Scholar]
  94. Lai J, Porreca F, Hunter JC, Gold MS. 94.  2004. Voltage-gated sodium channels and hyperalgesia. Annu. Rev. Pharmacol. Toxicol. 44:371–97 [Google Scholar]
  95. Gereau RW, Sluka KA, Maixner W, Savage SR, Price TJ. 95.  et al. 2014. A pain research agenda for the 21st century. J. Pain 15:1203–14 [Google Scholar]
  96. 96. Natl. Inst. Health. 2017. Estimates of funding for various research, condition, and disease categories (RCDC) NIH Categorical Spend. https://report.nih.gov/categorical_spending.aspx
/content/journals/10.1146/annurev-pharmtox-010617-052534
Loading
/content/journals/10.1146/annurev-pharmtox-010617-052534
Loading

Data & Media loading...

  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error